EUVIMEDEUVIMED entdecken
Crossref

Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure

Yabing Cao, Yunjing Sun, Bo Miao, Xiao Zhang, Qingzhou Zhao, Liping Qi, Yaoqi Chen, Lingling Zhu

American Journal of Translational Research · 2026 · 18 (10) · 9530-9541

DOI: 10.62347/cqek6090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Yabing Cao und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Cao, Y., Sun, Y., Miao, B., Zhang, X., Zhao, Q., Qi, L., Chen, Y., & Zhu, L. (2026). Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure. American Journal of Translational Research, 18(10), 9530-9541. https://doi.org/10.62347/cqek6090

Vancouver

Cao Y, Sun Y, Miao B, Zhang X, Zhao Q, Qi L, et al. Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure. American Journal of Translational Research. 2026;18(10):9530-9541. doi:10.62347/cqek6090

BibTeX
@article{Cao2026,
  author = {Cao, Yabing and Sun, Yunjing and Miao, Bo and Zhang, Xiao and Zhao, Qingzhou and Qi, Liping and Chen, Yaoqi and Zhu, Lingling},
  title = {Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure},
  journal = {American Journal of Translational Research},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {9530--9541},
  doi = {10.62347/cqek6090}
}
Kostenlos starten →